T-cell immune reconstitution (IR) after allogeneic hematopoietic cell transplantation (allo-HCT) is highly variable between patients and may take several months to even years. Patients with delayed or unbalanced T-cell IR have a higher probability of developing transplantation-related-morbidity, -mortality, and relapse of disease. Hence, there is a need for strategies to better predict and improve IR to reduce these limitations of allo-HCT. In this review, we provide an update of current and in near-future clinically relevant strategies before, during, and after transplantation to achieve successful T-cell IR. Potent strategies are choosing the right HCT-source (e.g. donor-recipient matching, cell-dose, graft manipulation), individualized conditioning and serotherapy (e.g. Anti-Thymocyte-Globulin), nutritional status, exercise, home care, modulation of microbiota, enhancing homeostatic peripheral expansion, promoting thymopoiesis, and the use of adjuvant targeted cellular immunotherapies. Strategies to prevent Graft-versus-Host-Disease (GvHD) are important as well, for this complication and subsequent need for immunosuppression affects T-cell IR and function. These options aim for personalized precisiontransplantation, where allo-HCT therapy is designed to boost a well-balanced T-cell IR and limit complications in individual patients, resulting in overall lower morbidity and higher survival chances.
Introduction
could be enhanced by optimizing the dosage of these chemotherapeutics via pharmacokinetic anddynamic modelling, and thymic shielding during irradiation, aiming for minimal thymic damage.
Furthermore, some chemotherapy with longer half-life (e.g. Fludarabine) may still be present during the infusion of the cells and can subsequently deplete T-cells in vivo. Also sex steroid hormone ablation may be applied to prevent thymic damage by chemotherapy/irradiation (described below).
Individualized serotherapy to improve T-cell IR
ATG was introduced to the conditioning regimen for in vivo TCD, to reduce GvHD risk, which can reach a cumulative incidence of over 40-70% even with a well-matched unrelated donor. A major drawback of conditioning with serotherapy is a hampered early T-and B-cell recovery. 48, 49 This effect is partly through direct binding and killing of T-and B-cells, but also through ''off-target'' cytotoxic effects on thymus cells, affecting thymopoiesis. 50 However, abandoning ATG from the conditioning is associated with significantly higher incidences of graft rejection and GvHD. 51 Recently, high ATG-exposure after allo-HCT was associated with detrimental effects on IR. 38 The highly variable pharmacokinetics of ATG between patients causes under-or over-exposure in a significant number of patients. 52 CB-cells were affected more by ATG compared to BM/PB; the tolerated post-HCT ATG-exposure, that does not affect IR, is lower for CBT (<20 active units [AU]*day/mL) compared to BMT/PBCT (<50 AU*day/mL). 38 CBT without ATG, and CBT with very low ATG-exposure, were associated with excellent IR potential, 49,51 stressing the importance for individualization. Interestingly, these studies also suggest that not ATG-exposure after, but exposure before transplantation prevented GvHD (acute and chronic) in children, but also in adults (unpublished data). Sufficiently high exposure before CBT also prevented rejection. This indicates that there still is an important role for ATG, at least for HCT in non-malignant diseases for graft rejection prevention, but earlier in the conditioning. In adult BM/PB recipients, this positive effect from conditioning with ATG on lower GvHD risk, but negative effects on T-cell IR, was also found. 48, 53 In HCT for hematopoietic malignancies, the decreased T-cell IR from post-transplantation ATG should especially be avoided, as this increases relapse risk and decreases survival. 54, 55 Taken together, these data suggest that personalized ATG-dosing impacts T-cell IR potential after HCT, resulting in better survival chances.
Peri-Transplantation Factors Nutrition and Microbiotics
Despite careful assessment and food supplementation, nutritional deficiency is common in allo-HCT patients. Nutritional requirements increase (up to 130-150% of normal) due to catabolic stress, such as during IR and complications. 56-58 Post-HCT calorie intake is directly related to time of neutrophilengraftment, 56 and calorie requirements increase to ≥ 35 kcal/kg/day in addition to 1.5-2 g/kg/day of protein in the setting of GvHD.
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To maintain nutritional status during and after allo-HCT treatment, patients often receive enteral nutrition or total parenteral nutrition (TPN). 59 Recently, enteral nutrition in the form of an oral elemental diet showed to be superior to TPN in decreasing the duration and severity of mucositis and duration of hospitalization. 60 Even during intestinal GvHD, outcome (e.g. diarrhea and time to complete dietary recovery) after enteral nutrition was comparable to TPN. 61 TPN, compared to enteral nutrition, resulted in significantly higher morbidity and mortality. 58 Therefore, recent studies suggest that enteral nutrition, seems to be the best approach to maintain nutritional status after allo-HCT, even in patients with mucositis or intestinal GvHD. Recent studies investigating the relation between intestinal microbiotics and GvHD in the human HCTsetting found that a lower diversity of microbiota relates to a higher risk of GvHD and mortality.
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Specifically, a shift towards higher presence of Enterococcus faecium and Enterococcus faecalis was found in GvHD patients, 69 while genus Blautia bacteria was associated with a lower probability on GvHD. 70 Therefore, choosing the right antibiotic regime may be of importance for its effects on microbiome diversity and GvHD-probability. 71 As pre-and probiotics maintain and restore microbiotic diversity, the use of probiotics to reduce GvHD risk is currently under investigation. The first results indicate that probiotic treatment prior to and after allo-HCT is safe, 72 and might even reduce GvHD severity associated with better T-cell IR.
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Exercise and Home care
Daily exercise before-and after HCT may fasten T-cell IR, 73 although not all studies found a significant effect. 74 Nevertheless, there is evidence indicating beneficial effects of physical exercise in the distribution and function of immune cells in healthy subjects. 75 Prospective trials are warranted to prove this.
Some advantageous effects of home care in the neutropenic phase of the treatment are reported. Home care correlated with lower aGvHD incidence, and survival was at least as high as historic controls.
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Especially since home care would improve quality of life, reduce costs, and shows to be safe, further research on outcome and the effect on IR would be of interest.
Post-Transplantation Interventions
For T-cell recovery, homeostatic peripheral expansion is the most important mechanism in absence of thymopoiesis, which takes at least 6-12 months. Improving HPE will, therefore, ultimately improve early T-cell IR. Some cytokine-based therapies for improving IR through HPE are currently under investigation 
Improving T-cell IR through homeostatic peripheral expansion (HPE)
IL-2
Interleukin-2 (IL-2) was introduced in the HCT setting for it's role in the differentiation of T-cells into effector cells and promotion of T-, B-, and NK-cell proliferation. Although interleukin 2 (IL-2) can have severe side effects at higher dosage (e.g. capillary-leak syndrome), low-dose IL-2 administration after HCT reduced relapse probability, probably due to an increased GvL response. 81, 82 It also restored homeostasis of CD4+ T-cells, and increased Treg counts, associated with clinical improvement of cGvHD, while no adverse events were noted. 83,84 Therefore, low-dose IL-2 therapy may improve T-cell IR, contributing to GvL, without increasing GvHD-probability.
IL-15
IL-15 is another interesting cytokine for improving HPE, as it is important for the expansion of B-and Tcells and for the survival of NK-cells. In a murine HCT-model, IL-15 during the first month after HCT was associated with early T-cell and NK-cell IR. 85 In humans, no systemic IL-15 therapy after allo-HCT has been evaluated so far. Only IL-15-stimulated CD3/CD19-depleted graft-cells, from part of the HCTgraft, or IL-15-activated cytokine-induced killer cells have been studied, albeit in few patients.
Interestingly, this therapy increased NK, NKT, and T-cell numbers at 15 to 30 days after receipt, without exacerbating GvHD, 86 and showed GvL potential when given at the initiation of relapse. 87 IL-15-stimulation of stem cells would, therefore, be interesting to evaluate in future studies.
Improving T-cell IR through thymopoiesis
IL-7
The administration of IL-7 was investigated in the HCT setting, as it naturally promotes the differentiation and proliferation of naïve T-cells. Treatment with recombinant IL-7 after HCT enhanced TCR-diversity, induced a doubling of (mainly memory) CD4 and CD8 T-cells, with no effects on Tregs, NK-, or B-cells. 88 Interestingly, IL-7 also increased the amount of functional T-cells, including virus-for treatment of chronic hepatitis B, with no adverse effects found in recipients from 13 months to 99 years old. 94 In the human HCT-setting, Tα1 administration shows encouraging first results on T-cell IR.
Subcutaneous administrations of Tα1, twice weekly for 4 weeks after allo-HCT, caused an increased CD4+ T-cell recovery and pathogen-specific T-cells to appear already at 1 month after HCT, which was earlier and in higher levels compared to controls. 95 Additionally, Tα1 lowered the cumulative incidence of non-relapse-mortality (mainly infection-related) and increased event-free-survival. 94 ,95 Therefore, Tα1 therapy might be a promising novel therapy to enhance T-cell IR after allo-HCT.
Cellular immunotherapies to improve immunity
The lack of effector immune cells after allo-HCT may be compensated with adjuvant cell-based immunotherapies. Due to high costs, regulatory burden, and complicated production, cellular immunotherapies are currently not widely being used in the HCT-setting. They mainly have potency to be used to treat life-threatening complications such as relapse, viral reactivations, GvHD, but could also be used prophylactically. Here, we discuss the currently most potent cellular immunotherapies to improve immunity after allo-HCT (Figure 3 ).
DC-vaccination
Dendritic cells (DCs) are highly specialized antigen-presenting-cells (APCs) that regulate the balance between action (relevant for GvL) and suppression of the immune system (relevant for GvHD). 
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For
NK-cells
Adoptive NK-cell immunotherapy in the allo-HCT setting is under investigation as well. Results from one of the earliest studies suggest limited adverse events and no induction of GvHD. 104 
NKT-cells
For their immunomodulatory properties, immunotherapy using natural-killer-T (NKT)-cells could be useful in the allo-HCT setting as well. NKT-cells play a role in both tumor surveillance and GvHD, 106 with early reconstitution suggested to be predictive of lower relapse and GvHD risk, and higher survival. 107, 108 Clinical trials implementing expanded NKT-cells in the allo-HCT setting are currently underway.
Engineered T-cells
One method to improve T-cell recovery is donor lymphocyte infusion (DLI). This non-specific T-cell
therapy is, however, associated with increased risk on GvHD. 109 Furthermore, because of the low frequency of T-cells reactive against many common viruses within the circulation, higher DLI doses may be required to confer clinical benefit against viruses, consequently increasing the risk of GvHD.
A more targeted method to enhance T-cell immunity after allo-HCT is with adoptively transferred antigen-specific T-cells. These T-cells can be expanded ex vivo after stimulation with APCs presenting specific antigens, such as cytomegalovirus, epstein-bar-virus, and adenovirus, 110 or against malignant cells to induce GvL. 111 A drawback of this therapy is the long time needed for production of specific Tcells. Gamma capture, based on IFN-γ production, of functional antigen-specific T-cells from a donor is a faster alternative. But for this method the presence of specific T-cells is essential and demands a seropositive donor. This is a challenge when the donor lacks viral immunity, or with CB which generally contains virus-naïve immune cells. Nevertheless, virus-specific T-cells can also be cultured from naïve CB T-cells. 112 
Another way is T-cell gene therapy to produce Chimeric Antigen Receptor (CAR) T-cells or engineer Tcells to express specific TCRs (TCR-T-cells). Based on the chosen CAR or TCR binding domain these modified T-cells can be used to target viruses and leukemic cells to target relapse (e.g. CART19, WT1-TCR-T-cells)
. [113] [114] [115] But they can potentially also be used as an alternative myeloablative therapy.
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For personal use only. on October 28, 2017. by guest www.bloodjournal.org From Drawbacks of genetically modified T-cell therapy, however, are possible cytotoxic effects on normal cells that express target antigens. 115 Nevertheless, the specificity and potency of this therapy is shown by the finding that donor-derived anti-CD19-CAR T-cells induce complete remission in relapsed patients, without exacerbating GvHD. 117 In addition, these cells have been shown to persist for over 3 years providing long-term protection against their target.
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Tregs and MSCs
Tregs and Mesenchymal stromal/stem cells (MSCs) can inhibit immune responses, and have been investigated as adjuvant cell-therapies to treat or prevent GvHD. The non-specific MSC therapy did not prevent GvHD when co-transplanted alongside the HCT-graft, 118 while even increased relapse rates and mortality were noted. 119 However, reduced aGvHD risk was seen when given after HCT before GvHDonset. 120 Co-infusion of Tregs alongside the HCT-graft decreased the occurrence of acute-and chronic GvHD, while maintaining GvL. 121, 122 This also resulted in high frequencies of pathogen-specific CD4+
and CD8+ T-cells already at 2 months after HCT, decreased incidence of CMV disease, and showed strong antiviral protection after pandemic influenza vaccination. 122 No negative effects due to the Treg infusion were reported. Furthermore, transplantation with CB-derived Tregs directly after CBT showed an increase in viral infections within 30 days infusion, but lowered the occurrence of GvHD without increased risk of relapse. 121, 123 This may make Treg-immunotherapy a promising strategy to decrease the risk for GvHD associated with better T-cell IR potential.
Concluding remarks and future perspective
We have summarized a broad variety of novel strategies before, during, and after HCT to improve T-cell IR, aiming to decrease the risk of complications and increase survival chances. Selecting the appropriate HCT source, and graft manipulations, are the first critical factors affecting T-cell IR after transplantation.
Individualizing the conditioning regimen is crucial as well, especially for compounds that dramatically influence T-cell IR, such as ATG. Furthermore, enhancing homeostatic peripheral expansion, preventing thymic damage, and promoting thymopoiesis are important in enhancing T-cell IR. Better disease control may be achieved with adjuvant (specific) cellular immunotherapies to prevent GvHD and promote immunity against pathogens and cancer cells. Probably a combination of these pre-, peri-, and post-HCT strategies will most potently enable a timely and balanced T-cell recovery.
Immunomonitoring will be of major importance to identify patients at risk, which would provide opportunities for early immune interventions. For instance, patients with low T-cell counts early after HCT, and/or a low TCR-diversity, are at risk for HCT-related complications and could benefit from
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From adjuvant immunotherapies; such as low-dose IL-2, administration of Tregs, or leukemia/virus-specific DCs and/or -specific-T-cells. New functional measures of immune-recovery would, therefore, also add to guide clinicians in the assessment of IR beyond simple absolute lymphocyte counts. In addition, it is important to continue adequate supportive care with continuation of anti-microbial prophylaxis and PCR monitoring for viruses until adequate immune recovery occurs.
Standardization and harmonization of immunomonitoring would enable better comparison between multiple allo-HCT studies, in order to better understand the biology of IR, and find biomarkers. 124 These biomarkers will help the physician to guide the developing immune system, and anticipate on complications in order to avert them. This will pave the path to precision-transplantation in the future; in which allo-HCT therapy will be personalized, using a combination of strategies to boost T-cell IR, subsequently resulting in lower morbidity and higher survival after allo-HCT.
cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. 
